Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

pembrolizumab 26Nivolumab 10Docetaxel 8avelumab 7atezolizumab 7Gemcitabine 7Carboplatin 6Trastuzumab 5Ipilimumab 5Radiosurgery 4Psychiatric Rehabilitation 4Immunoglobulin G 4Early Intervention, Educational 4Cyclophosphamide 4fludarabine 3durvalumab 3cemiplimab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Disulfides 3Counseling 3Cisplatin 3Blood Specimen Collection 3Biopsy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3zimberelimab 2utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × tovorafenib × Thoracic × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡